Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steen Pehrson

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
American Heart Journal|November 4, 2020
Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failure-Results from the DANISH trialRune Boas, Jens Jakob Thune, Steen Pehrson, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|December 1, 2020
Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trialRune Boas, Jens Jakob Thune, Steen Pehrson, et al.
European Journal of Heart Failure|May 11, 2024
New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trialMunise N Karacan, Seiko N Doi, Adelina Yafasova, et al.
Journal of Cardiac Failure|May 16, 2024
Effect of Implantable Cardioverter-defibrillators in Nonischemic Heart Failure According to Background Medical Therapy: Extended Follow-up of the DANISH TrialAdelina Yafasova, Seiko N Doi, Jens Jakob Thune, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 20, 2019
The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failureRasmus Rørth, Jens Jakob Thune, Jens C Nielsen, et al.
JACC. Heart Failure|March 7, 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
Journal of the American College of Cardiology|October 22, 2025
Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISHJawad H Butt, Seiko N Doi, Jens J Thune, et al.
Circulation|August 30, 2021
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialMilton Packer, Javed Butler, Faiez Zannad, et al.
JACC. Heart Failure|February 3, 2025
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
Journal of the American Heart Association|January 31, 2024
Estimated Glomerular Filtration Rate and Implantable Cardioverter-Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow-Up of DANISHSeiko N Doi, Jens Jakob Thune, Jens C Nielsen, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
American Heart Journal|November 4, 2020
Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failure-Results from the DANISH trialRune Boas, Jens Jakob Thune, Steen Pehrson, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|December 1, 2020
Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trialRune Boas, Jens Jakob Thune, Steen Pehrson, et al.
European Journal of Heart Failure|May 11, 2024
New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trialMunise N Karacan, Seiko N Doi, Adelina Yafasova, et al.
Journal of Cardiac Failure|May 16, 2024
Effect of Implantable Cardioverter-defibrillators in Nonischemic Heart Failure According to Background Medical Therapy: Extended Follow-up of the DANISH TrialAdelina Yafasova, Seiko N Doi, Jens Jakob Thune, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|July 20, 2019
The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failureRasmus Rørth, Jens Jakob Thune, Jens C Nielsen, et al.
JACC. Heart Failure|March 7, 2023
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
Journal of the American College of Cardiology|October 22, 2025
Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISHJawad H Butt, Seiko N Doi, Jens J Thune, et al.
Circulation|August 30, 2021
Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialMilton Packer, Javed Butler, Faiez Zannad, et al.
JACC. Heart Failure|February 3, 2025
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved TrialPeter Carson, John R Teerlink, Michel Komajda, et al.
Journal of the American Heart Association|January 31, 2024
Estimated Glomerular Filtration Rate and Implantable Cardioverter-Defibrillator in Nonischemic Systolic Heart Failure: Extended Follow-Up of DANISHSeiko N Doi, Jens Jakob Thune, Jens C Nielsen, et al.
Pageof 11